08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Edison, Dainippon Sumitomo deal

Dainippon will pay Edison $10 million up front and $40 million in R&D support in exchange for exclusive rights in Japan and North America to develop and commercialize three compounds targeting cellular energy metabolism to...
01:35 , Feb 1, 2014 |  BC Extra  |  Company News

Edison, Dainippon add discovery deal

Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506) will pay Edison Pharmaceuticals Inc. (Mountain View, Calif.) $10 million up front and provide $40 million in R&D support in exchange for exclusive rights in Japan and North America...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Edison, Dainippon Sumitomo deal

Edison granted Dainippon exclusive rights to develop and commercialize EPI-743 and EPI-589 in Japan. Edison, which retains rights to the compounds outside of Japan, will receive $35 million up front and $15 million in R&D...
00:12 , Mar 29, 2013 |  BC Extra  |  Top Story

Edison licenses two candidates to Dainippon

Edison Pharmaceuticals Inc. (Mountain View, Calif.) granted Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) exclusive rights to develop and commercialize EPI-743 and EPI-589 in Japan. Edison, which retains rights to the compounds outside of Japan,...